GT200600148A - Metodos para el tratamiento y la prevencion de fibrosis - Google Patents
Metodos para el tratamiento y la prevencion de fibrosisInfo
- Publication number
- GT200600148A GT200600148A GT200600148A GT200600148A GT200600148A GT 200600148 A GT200600148 A GT 200600148A GT 200600148 A GT200600148 A GT 200600148A GT 200600148 A GT200600148 A GT 200600148A GT 200600148 A GT200600148 A GT 200600148A
- Authority
- GT
- Guatemala
- Prior art keywords
- fibrosis
- prevention
- treatment
- methods
- affection
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 3
- 230000004761 fibrosis Effects 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 abstract 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000010187 selection method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA MÉTODOS DE SELECCIÓN PARA COMPOSICIONES ÚTILES PARA EL TRATAMIENTO, ALIVIO O PREVENCIÓN DE LA FIBROSIS Y/O AFECCIÓN ASOCIADA CON LA FIBROSIS MIDIENDO LOS CAMBIOS EN LOS NIVELES DE IL-21 Y/O RECEPTOR DE IL-21 (IL-21R). T2006
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67137405P | 2005-04-14 | 2005-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600148A true GT200600148A (es) | 2006-11-22 |
Family
ID=36741387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600148A GT200600148A (es) | 2005-04-14 | 2006-04-10 | Metodos para el tratamiento y la prevencion de fibrosis |
Country Status (22)
Country | Link |
---|---|
US (2) | US7910105B2 (es) |
EP (2) | EP1871800A1 (es) |
JP (1) | JP2008538553A (es) |
KR (1) | KR20080017009A (es) |
CN (1) | CN101287759A (es) |
AR (1) | AR057274A1 (es) |
AU (1) | AU2006236755A1 (es) |
BR (1) | BRPI0609762A2 (es) |
CA (1) | CA2604604A1 (es) |
CR (1) | CR9428A (es) |
GT (1) | GT200600148A (es) |
IL (1) | IL186599A0 (es) |
MX (1) | MX2007012842A (es) |
NI (1) | NI200700259A (es) |
NO (1) | NO20075193L (es) |
NZ (1) | NZ562333A (es) |
PE (1) | PE20070316A1 (es) |
RU (1) | RU2419450C2 (es) |
SG (1) | SG161286A1 (es) |
TW (1) | TW200716171A (es) |
WO (1) | WO2006113331A1 (es) |
ZA (1) | ZA200708756B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
BR0312738A (pt) * | 2002-07-15 | 2007-06-26 | Wyeth Corp | processos e composições para a modulação do desenvolvimento e da função de células t auxiliares (th) |
JP4914209B2 (ja) * | 2003-03-14 | 2012-04-11 | ワイス | ヒトil−21受容体に対する抗体および該抗体の使用 |
KR20060015482A (ko) * | 2003-03-21 | 2006-02-17 | 와이어쓰 | 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료 |
AU2005244942A1 (en) * | 2004-05-19 | 2005-12-01 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
BRPI0514138A (pt) * | 2004-08-05 | 2008-05-27 | Wyeth Corp | método para tratar, melhorar, ou prevenir um distúrbio, proteìna de fusão, vetor, célula hospedeira recombinante, método para produzir uma proteìna de fusão, composição farmacêutica, e, métodos para transplantar/enxertar um órgão, tecido, célula ou grupo de células em um indivìduo mamìfero, e para tratar, prevenir ou melhorar rejeição de transplante/enxerto em um receptor de transplante/enxerto mamìfero |
EP2182943B1 (en) * | 2007-07-23 | 2016-10-26 | Janssen Biotech, Inc. | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
WO2009047360A1 (en) * | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
EP2296689A1 (en) * | 2008-05-23 | 2011-03-23 | Wyeth LLC | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
AR071885A1 (es) * | 2008-05-23 | 2010-07-21 | Wyeth Corp | Proteinas de union al receptor de interleuquina 21 |
WO2010051550A1 (en) * | 2008-10-31 | 2010-05-06 | University Of Rochester | Methods of diagnosing and treating fibrosis |
WO2011050263A2 (en) * | 2009-10-23 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Systemic immunosuppression in the treatment of age related macular degeneration and diabetic retinopathy |
WO2012099886A1 (en) | 2011-01-18 | 2012-07-26 | Bioniz, Llc | Compositions and mehthods for modulating gamma-c-cytokine activity |
CN102532320A (zh) * | 2012-03-06 | 2012-07-04 | 中国药科大学 | 全人源的抗人白介素21受体的单链抗体及其应用 |
RU2020111934A (ru) * | 2013-10-08 | 2020-04-29 | Промедиор, Инк. | Способы лечения фиброзного рака |
US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
WO2015110930A1 (en) * | 2014-01-24 | 2015-07-30 | Pfizer Inc. | Modified interleukin 21 receptor proteins |
KR101756417B1 (ko) | 2014-08-21 | 2017-07-10 | 한국유나이티드제약 주식회사 | 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물 |
JP6863974B2 (ja) | 2015-10-09 | 2021-04-21 | バイオニズ リミテッド ライアビリティー カンパニー | γcサイトカイン活性の調節 |
RU2019109019A (ru) | 2016-08-31 | 2020-10-01 | Тобира Терапьютикс, Инк. | Твердые формы ценикривирок мезилата и способы изготовления твердых форм ценикривирок мезилата |
US20210113660A1 (en) * | 2018-05-07 | 2021-04-22 | Olives Biotherapeutics Inc. | Pharmaceutical composition comprising ccn5 as active ingredient, for preventing or treating retinal diseases |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
AU664976B2 (en) | 1990-08-29 | 1995-12-14 | Gene Pharming Europe Bv | Homologous recombination in mammalian cells |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5399677A (en) | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
HU221984B1 (hu) | 1996-02-09 | 2003-03-28 | Basf Ag | Humán TNFalfa-t kötő antitestek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
US6350892B1 (en) | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
US7189400B2 (en) | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
US6576744B1 (en) | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
CN101575377B (zh) | 1999-03-09 | 2012-12-26 | 津莫吉尼蒂克斯公司 | 作为zalpha受体之配体的人细胞因子及其用途 |
US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
TR200603997T1 (tr) | 1999-03-25 | 2010-01-21 | Abbott Gmbh & Co. Kg | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
CA2398561A1 (en) | 2000-01-27 | 2001-08-02 | American Cyanamid Company | Method for preparing alpha-sulfonyl hydroxamic acid derivatives |
DE60141234D1 (de) | 2000-04-05 | 2010-03-18 | Zymogenetics Inc | Löslicher Zytokinrezeptor zalpfa11 |
DE60124954T2 (de) | 2000-05-11 | 2007-09-20 | Genetics Institute, LLC, Cambridge | Mu-1, ein mitglied der cytokine rezeptor familie |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
US20040058445A1 (en) | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
JP2005508915A (ja) * | 2001-10-04 | 2005-04-07 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | インターロイキン21受容体活性を調節する方法および組成物 |
DK1451322T3 (da) | 2001-11-05 | 2010-02-01 | Zymogenetics Inc | Il-21-antagonister |
WO2003087320A2 (en) | 2002-04-09 | 2003-10-23 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
US20040016010A1 (en) | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
EP2377549A1 (en) | 2002-06-07 | 2011-10-19 | ZymoGenetics, Inc. | Use of IL-21 for treating viral infections |
BR0312738A (pt) | 2002-07-15 | 2007-06-26 | Wyeth Corp | processos e composições para a modulação do desenvolvimento e da função de células t auxiliares (th) |
JP4914209B2 (ja) | 2003-03-14 | 2012-04-11 | ワイス | ヒトil−21受容体に対する抗体および該抗体の使用 |
KR20060015482A (ko) | 2003-03-21 | 2006-02-17 | 와이어쓰 | 인터루킨-21/인터루킨-21 수용체의 작용제를 이용한면역장애의 치료 |
WO2005030196A2 (en) | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
AU2005244942A1 (en) | 2004-05-19 | 2005-12-01 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
BRPI0514138A (pt) * | 2004-08-05 | 2008-05-27 | Wyeth Corp | método para tratar, melhorar, ou prevenir um distúrbio, proteìna de fusão, vetor, célula hospedeira recombinante, método para produzir uma proteìna de fusão, composição farmacêutica, e, métodos para transplantar/enxertar um órgão, tecido, célula ou grupo de células em um indivìduo mamìfero, e para tratar, prevenir ou melhorar rejeição de transplante/enxerto em um receptor de transplante/enxerto mamìfero |
WO2009100035A2 (en) | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
2006
- 2006-04-10 GT GT200600148A patent/GT200600148A/es unknown
- 2006-04-12 AR ARP060101469A patent/AR057274A1/es not_active Application Discontinuation
- 2006-04-13 SG SG201002668-0A patent/SG161286A1/en unknown
- 2006-04-13 KR KR1020077026544A patent/KR20080017009A/ko not_active Application Discontinuation
- 2006-04-13 US US11/402,885 patent/US7910105B2/en not_active Expired - Fee Related
- 2006-04-13 JP JP2008506683A patent/JP2008538553A/ja active Pending
- 2006-04-13 EP EP06750009A patent/EP1871800A1/en not_active Withdrawn
- 2006-04-13 AU AU2006236755A patent/AU2006236755A1/en not_active Abandoned
- 2006-04-13 BR BRPI0609762-6A patent/BRPI0609762A2/pt not_active IP Right Cessation
- 2006-04-13 TW TW095113160A patent/TW200716171A/zh unknown
- 2006-04-13 NI NI200700259A patent/NI200700259A/es unknown
- 2006-04-13 NZ NZ562333A patent/NZ562333A/en not_active IP Right Cessation
- 2006-04-13 CN CNA2006800210906A patent/CN101287759A/zh active Pending
- 2006-04-13 WO PCT/US2006/013829 patent/WO2006113331A1/en active Application Filing
- 2006-04-13 RU RU2007138011/14A patent/RU2419450C2/ru not_active IP Right Cessation
- 2006-04-13 MX MX2007012842A patent/MX2007012842A/es not_active Application Discontinuation
- 2006-04-13 CA CA002604604A patent/CA2604604A1/en not_active Abandoned
- 2006-04-13 EP EP11182581A patent/EP2436695A1/en not_active Withdrawn
- 2006-04-17 PE PE2006000401A patent/PE20070316A1/es not_active Application Discontinuation
-
2007
- 2007-10-09 CR CR9428A patent/CR9428A/es not_active Application Discontinuation
- 2007-10-11 IL IL186599A patent/IL186599A0/en unknown
- 2007-10-11 NO NO20075193A patent/NO20075193L/no not_active Application Discontinuation
- 2007-10-12 ZA ZA200708756A patent/ZA200708756B/xx unknown
-
2011
- 2011-02-18 US US13/030,840 patent/US20110142833A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CR9428A (es) | 2008-02-20 |
US20060257403A1 (en) | 2006-11-16 |
US20110142833A1 (en) | 2011-06-16 |
WO2006113331A1 (en) | 2006-10-26 |
EP2436695A1 (en) | 2012-04-04 |
NZ562333A (en) | 2011-04-29 |
ZA200708756B (en) | 2008-09-25 |
US7910105B2 (en) | 2011-03-22 |
JP2008538553A (ja) | 2008-10-30 |
RU2007138011A (ru) | 2009-05-20 |
AU2006236755A1 (en) | 2006-10-26 |
PE20070316A1 (es) | 2007-04-16 |
CA2604604A1 (en) | 2006-10-26 |
NI200700259A (es) | 2009-03-03 |
EP1871800A1 (en) | 2008-01-02 |
SG161286A1 (en) | 2010-05-27 |
AR057274A1 (es) | 2007-11-28 |
KR20080017009A (ko) | 2008-02-25 |
MX2007012842A (es) | 2007-11-20 |
IL186599A0 (en) | 2008-01-20 |
NO20075193L (no) | 2008-01-11 |
BRPI0609762A2 (pt) | 2010-04-27 |
RU2419450C2 (ru) | 2011-05-27 |
CN101287759A (zh) | 2008-10-15 |
TW200716171A (en) | 2007-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600148A (es) | Metodos para el tratamiento y la prevencion de fibrosis | |
ATE528989T1 (de) | Kristalline feste rasagilin-base | |
CY1114690T1 (el) | Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων | |
GB2453058A (en) | Kinase antagonists | |
HN2008000311A (es) | Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
BR112012008385A2 (pt) | inibidores de p13 cinase e uso dos mesmos. | |
TW200745161A (en) | Stable antibody formulation | |
GT200600264A (es) | Modificaciones cristalinas de piraclostrobina | |
HN2005035605A (es) | Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios | |
DK1778236T3 (da) | Modificerede pyrimidin-glucocorticoid-receptor-modulatorer | |
DK1881985T3 (da) | Vandfrie krystalliske former af N-Y1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-D]pyrimidin-3-carbonyl¨methansulfonamid | |
EA200702529A1 (ru) | Фунгицидная комбинация биологически активных веществ | |
MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
CR10530A (es) | Anticuerpos anti-dlla4 y metodos que los usan | |
MX2007002675A (es) | Antagonistas anti-beta7 humanizados y usos para los mismos. | |
CR8986A (es) | Isoxazoles sustituidos como fungicidas | |
GB0515353D0 (en) | Food | |
TW200727920A (en) | New regimens for oral monophasic contraceptives | |
MX2010003242A (es) | Volatiles vegetales. | |
WO2006034113A3 (en) | Quinolone analogs as cell proliferation inhibitors | |
TNSN07222A1 (en) | Nematicidal compositions | |
MX2007008723A (es) | Polipeptidos de yersinia spp y metodos de uso. | |
UA85505C2 (en) | Kinase inhibitors | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same |